TransMedics Group (TMDX) Projected to Post Quarterly Earnings on Thursday

TransMedics Group (NASDAQ:TMDX) is projected to post its Q3 2026 results after the market closes on Thursday, November 5th. Analysts expect TransMedics Group to announce earnings of $0.2976 per share and revenue of $178.06 million for the quarter. Investors may review the information on the company’s upcoming Q3 2026 earnings overview page for the latest details on the call scheduled for Thursday, November 5, 2026 at 4:30 PM ET.

TransMedics Group (NASDAQ:TMDX) last issued its quarterly earnings data on Tuesday, August 4th. The company reported $0.44 EPS for the quarter, missing the consensus estimate of $0.50 by ($0.06). The company had revenue of $189.95 million during the quarter, compared to the consensus estimate of $184.00 million. TransMedics Group had a return on equity of 15.88% and a net margin of 22.69%. The firm’s revenue for the quarter was up 20.7% compared to the same quarter last year. During the same quarter last year, the company posted $0.92 earnings per share. On average, analysts expect TransMedics Group to post $1.46 EPS for the current fiscal year and $2.26 EPS for the next fiscal year.

TransMedics Group Trading Up 1.0%

Shares of TMDX opened at $67.34 on Wednesday. The firm’s 50-day moving average price is $80.57 and its 200-day moving average price is $94.17. The firm has a market capitalization of $2.33 billion, a price-to-earnings ratio of 33.84, a PEG ratio of 0.92 and a beta of 2.14. The company has a current ratio of 6.62, a quick ratio of 6.07 and a debt-to-equity ratio of 1.62. TransMedics Group has a 1-year low of $60.10 and a 1-year high of $156.00.

Insider Activity at TransMedics Group

In related news, Director David Weill purchased 1,336 shares of the business’s stock in a transaction that occurred on Friday, September 11th. The shares were bought at an average price of $81.63 per share, for a total transaction of $109,057.68. Following the purchase, the director directly owned 16,392 shares of the company’s stock, valued at approximately $1,338,078.96. This represents a 8.87% increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. 6.90% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

A number of equities analysts recently issued reports on TMDX shares. TD Cowen reissued a “buy” rating and issued a $120.00 price target on shares of TransMedics Group in a research note on Tuesday, September 8th. Canaccord Genuity Group lowered their price objective on shares of TransMedics Group from $95.00 to $94.00 and set a “buy” rating for the company in a report on Tuesday, October 13th. Needham & Company LLC reaffirmed a “buy” rating on shares of TransMedics Group in a research report on Friday, September 11th. Barclays assumed coverage on TransMedics Group in a research report on Wednesday, October 7th. They set an “overweight” rating and a $120.00 price objective on the stock. Finally, Piper Sandler reiterated an “overweight” rating and set a $100.00 target price (down from $120.00) on shares of TransMedics Group in a report on Wednesday, August 5th. Five equities research analysts have rated the stock with a Buy rating, six have issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the company currently has an average rating of “Hold” and a consensus price target of $115.60.

About TransMedics Group

TransMedics Group, Inc is a medical technology company focused on improving organ transplantation through systems that preserve and assess donor organs outside the body. The company’s primary platform is the Organ Care System (OCS), a portable, technology-enabled perfusion system designed to maintain organs in a functioning, near-physiologic state during transport and evaluation.

TransMedics offers OCS products for heart, lung and liver transplantation. Its systems are intended to support the use of organs that may not otherwise be suitable for conventional cold-storage methods, potentially expanding the donor pool and providing transplant teams with additional information when evaluating organs for transplantation.

Founded in 1998 and headquartered in Andover, Massachusetts, TransMedics serves transplant centers in the United States and select international markets.